GlassScriptPhysician profile
Timothy R Tuel
NPI 1073598884
$19,708.18
in general payments reported to CMS, 2019-2025
57 companies · $2,667 in 2025
The $2,667 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,126 · 2020: $2,899 · 2021: $4,046 · 2022: $2,338 · 2023: $2,479 · 2024: $2,154 · 2025: $2,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,299.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,062.77 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Amgen INC. | $1,803.08 | 2019-2022 | |
| Abbvie INC. | $1,786.95 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $1,659.26 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,329.59 | 2019-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $1,031.21 | 2019-2024 | Invega Trinza, Invega Sustenna, Spravato |
| Glaxosmithkline, LLC. | $943.09 | 2019-2023 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $850.01 | 2023-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $763.87 | 2019-2022 | |
| Axsome Therapeutics, INC. | $737.03 | 2023-2025 | Auvelity, Sunosi |
| Pfizer INC. | $732.66 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $534.02 | 2019-2023 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.62 | 2020-2025 | |
| Vanda Pharmaceuticals INC. | $386.10 | 2019-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $323.62 | 2023-2025 | Quviviq, Quviviq |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Tuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.